Objective To evaluate the clinical efficacy of thalidomide combined with VAD chemotherapy for multiple myeloma. Methods 149 articles retrieve and read the title, abstract after setting the search conditions. 32 articles were selected. The final total of 10 articles were selected after reading more and excluded IS articles with standard non-standard statistical methods error, not designed rigorous and duplicate published. The clinical data of 489 patients in the 10 articles were reviewed the clinical data of observation group of 250 cases and 239 cases of the control group were statistically analyzed. Results The partial remission rate of 489 patients of observation group and the control group were 52.8% (132/250) and 30.1% (72/239) respectively through statistical analysis, the difference was statistically significant (Z = 5.28, P＜ 0.01, OR = 2.77, 95%CI: 1.90 4.04). Total efficiency of the two groups were 81:2% (203/250) and 54.4% (130/239). The difference was statistically significant (Z = 6.61, P ＜ 0.01, OR - 3.92, 95%CI: 2.61-5.87). Conclusion Thalidomide combined with VAD chemotherapy has a well efficacy for multiple myeloma.%目的 评估沙利度胺联合VAD化疗方案对多发性骨髓瘤临床疗效.方法 设定检索条件后,检索149篇文献,阅读题目、摘要,纳入32篇文献,然后阅读全文,排除标准不规范、统计方法错误、设计不严谨和重复发表的文献18篇,最终共有10篇文献入选.系统回顾10篇文献中的489例患者临床资料,其中,观察组250例,对照组239例,对其临床资料进行统计学分析.结果 通过统计学分析发现,观察组和对照组489例患者部分缓解率分别为52.8%(132/250)和30.1%(72/239),差异有统计学意义(Z=5.28,P<0.01,OR=2.77,95%CI:1.90～4.04);总有效率分别为81.2%(203/250)和54.4%(130/239),差异有统计学意义(Z=6.61,P<0.01,OR=3.92,95%CI:2.61～5.87).结论 沙利度胺联合VAD化疗方案对多发性骨髓瘤有良好的疗效.
展开▼
